Expansion Opportunities Bimeda is rapidly expanding its North American presence through acquisitions and new product launches, including recent assets from Dechra and the launch of GASTROBIM and BOVitalize Plus. This indicates ongoing growth in U.S. markets and a need for expanded distribution, private label partnerships, and veterinary care products within large networks.

Private Label Potential With a track record of manufacturing private label for distributors and international companies, Bimeda leverages OEM capabilities that can be tapped for co-branded or white-label animal health solutions, creating opportunities for channel partners and regional distributors seeking differentiated offerings.

Therapeutic Portfolio Recent FDA-approved bioequivalent products like GASTROBIM for equine gastric ulcers demonstrate a focus on specialty therapies and competitive differentiation in tightly regulated segments, suggesting potential cross-sell of complementary GI, digestion, and performance products to existing customers and dealers.

Operational Footprint A global manufacturing footprint across nine facilities and a broad geographic reach supports supply security for international distributors and large-scale buyers, enabling scalable partnerships and multi-region contract manufacturing opportunities.

Talent and Tech Enablement New appointments in swine technical services and US technical leadership, coupled with a quality-focused tech stack (ISO certifications, regulated processes), position Bimeda to engage with veterinary clinics, large animal practices, and swine producers through enhanced technical service and training programs.